AskBio
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$1.6m | Grant | ||
$2.5m | Grant | ||
$235m | Late VC | ||
$4.0b Valuation: $4.0b | Acquisition | ||
Total Funding | CAD326m |
Related Content
Recent News about AskBio
EditAskBio, or Asklepios BioPharmaceutical, Inc., is a clinical stage gene therapy company focused on developing adeno-associated virus (AAV) gene therapies for both genetic and complex disorders. The company operates in the biotechnology sector, primarily serving patients with unmet medical needs. AskBio's business model revolves around research and development, clinical trials, and eventual commercialization of their gene therapy products. Revenue is generated through partnerships, licensing agreements, and future sales of approved therapies. The company is committed to advancing genetic technology and improving patient care through innovative treatments.
Keywords: gene therapy, AAV, biotechnology, clinical trials, genetic disorders, complex disorders, patient care, R&D, licensing, innovation.